Trial Profile

Safety and efficacy of direct oral anticoagulants (dabigatran, apixaban, rivaroxaban) versus vitamin K antagonists and molecular weight heparins (LMWHs) for the treatment of non-cirrhotic portal vein thrombosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Enoxaparin sodium; Vitamin K antagonists; Warfarin
Indications Thrombosis
Focus Therapeutic Use

30 Nov 2019 New trial record
06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com